echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Infection > FDA advisory body approves Johnson & Johnson's COVID-19 vaccine booster

    FDA advisory body approves Johnson & Johnson's COVID-19 vaccine booster

    • Last Update: 2021-10-19
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit

    The FDA advisory panel recently voted 19-0 to recommend the COVID-19 vaccine Ad26.
    S to all recipients 18 years and older to be boosted at least two months after receiving the single-dose initial injection

    Several committee members suggested that it should be treated as a two-dose vaccine, just like Pfizer/BioNTech’s Comirnaty and Moderna’s mRNA-1273

    FDA COVID-19

    Expert panel member Archana Chatterjee said: "A single dose of Ad26.
    S does not seem to provide sufficient protection like the mRNA vaccine, so it is indeed necessary to use a second dose to make it comparable to other vaccines in terms of effectiveness


    Johnson & Johnson has proposed that its vaccines should also be boosted after an interval of at least six months, but it is also recommended to be vaccinated within two months at the earliest

    In a briefing document issued before Friday's meeting, FDA scientists suggested that boosters should be given about two months later "may be beneficial," but questioned the company's data about a six-month interval between doses

    Johnson & Johnson, head of vaccine development Johan Van Hoof told the committee, six months after the first vaccination strengthen immunity , resulting in 12-fold increase in the antibody, and the effectiveness of its variants (including Delta) is also increased in proportion

    The company’s research results are based on 17 volunteers between the ages of 18 and 55.

    Immunity when the results of the company's research based on 17 volunteers aged between 18 and 55 years, and one pair of larger study of 51 subjects found that two months after the first dose given booster, Its antibody has increased by nearly 5 times

    At the same time, Johnson & Johnson executives Macaya Douoguih said there was no data show that people receiving the second dose Ad26.
    S troubles rare but serious risk of blood clotting disorders will increase

    She cited data from the United Kingdom on AstraZeneca's second dose of the coronavirus vaccine Vaxzevria, which uses a platform similar to Johnson & Johnson's vaccine

    The FDA may make a final decision on Johnson & Johnson's vaccine within a few days, and then it is expected that the CDC Vaccine Advisory Committee will meet to further discuss recommendations on who should receive the booster and when


    Original source:

    Original source:


    https://®ion_id=6 https://®ion_id=6 leave a message here
    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.